Tamoxifen-mediated anti-cellular effect against a choriocarcinoma cell line

International Journal of Oncology

Volumn 12, Issue 5, 1998, Pages 1171-1176

  Ho, Chi Kuan ^a   Chi, Chin Wen ^a,b   Yu, Ken Jen ^a,b   Wang, Sheng Yuan ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Choriocarcinoma cell line; Tamoxifen; Trophoblastic disease

Indexed keywords

ESTROGEN RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; MIFEPRISTONE; MUTANT PROTEIN; PLATELET DERIVED GROWTH FACTOR; PROGESTERONE RECEPTOR; PROTEIN P53; SOMATOMEDIN C; TAMOXIFEN; THYMIDINE; TRANSFORMING GROWTH FACTOR ALPHA; TRITIUM;

ARTICLE; CANCER CELL CULTURE; CHORIOCARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; FETAL CALF SERUM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TROPHOBLAST;

EID: 0031966543     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.5.1171     Document Type: Article

References (34)

1. Tora L, White J, Brou C, Tasser D, Webster N, Scheer E and Chambon P: The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59: 477-487, 1989.
2. Couldwell WT, Weiss MH, Di Giorgio LM, Weiner LP, Hinton DR, Ehsesmann LR, Corti PS and Apuzzo MLJ: Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 32: 485-490, 1993.
3. Freiss G, Rochefort H and Vignon F: Mechanisms of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: alterations of growth factor receptor binding sites and tyrosine kinase activity. Biochem Biophys Res Commun 173: 919-926, 1990.
4. Tsai MJ and O'Malley BW: Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63: 451-486, 1994.
5. Wakeling AE: Steroid antagonists as nuclear receptor blockers. Cancer Surv 14: 71-85, 1992.
6. Beato M: Transcriptional control by nuclear receptors. FASEB J 5: 2044-2051, 1991.
7. Perry RR, Kang Y and Greaves BR: Relationship between tamoxifen-induced transforming growth factor β1 expression, cytostasis and apoptosis in human breast cancer cells. Br J Cancer 72: 1441-1446, 1995.
8. Lim JS, Frenkel K and Troll W: Tamoxifen suppresses tumor promoter-induced hydrogen peroxide formation by human neutrophils. Cancer Res 52: 4969-4972, 1992.
9. Custodio JBA, Dinis TCP, Almeida LM and Madeira VMC: Tamoxifen and hydroxytamoxifen as intramembraneous inhibitors of lipid peroxidation evidence for peroxyl radical scavenging activity. Biochem Pharmacol 47: 1989-1998, 1994.
10. Wiseman H, Cannon M, Arnstein HRV and Halliwell B: Mechanism of inhibition of lipid peroxidation by tamoxifen and 4-hydroxytamoxifen introduced into liposomes. FEBS Lett 274: 107-110, 1990.
11. Pasqualini JR, Giambiagi N, Gelly C and Chetrite G: Anti-estrogen action in mammary cancer and in fetal cells. J Steroid Biochem Mol Biol 37: 343-348, 1990.
12. Ilgren EB: Review article: control of trophoblastic growth. Placenta 4: 307-328, 1983.
13. Goustin AS, Betsholtz C, Pfeifer-Ohlsson S, Persson H, Rydnert J, Bywater M, Holmgren G, Heldin CH, Westermark B and Ohlsson R: Coexpression of the sis and myc proto-oncogenes in developing human placenta suggests autocrine control of trophoblast growth. Cell 41: 301-312, 1985.
14. Shanklin DR: Tumors of placental epithelium. In: Tumors of the Placenta and Umbilical Cord. Decker Inc., Philadelphia, pp29-96, 1990.
15. Ho CK, Chiang H, Li SY, Yuan CC and Ng HT: Establishment and characterization of a tumorigenic trophoblast-like cell line from a human placenta. Cancer Res 47: 3220-3224, 1987.
16. Ho CK, Wang CC, Li SY, Chiang H, Yu KJ and Wang SY: Characterization of a human tumorigenic poorly differentiated trophoblast cell line. In Vitro 30A: 415-417, 1994.
17. Mosmann T: A rapid colorimetric assay for cellular growth and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
18. Ho CK, Au LC and Wang SY: Suppression of vincristine mediated cytotoxic activity by mitoxantrone in human cell lines. Anticancer Res 16: 2645-2652, 1996.
19. Lui WY, P'eng FK, Chang YF, Chang TJ, Tsai TF, Hsu ML, Su TS, Tsay SH, Wu CW, Liu TY and Chi CW: Analysis of glucocorticoid receptors in human heptocellular carcinoma and HepG2 cells. Hepatology 18: 1167-1174, 1993.
20. Wang SY, Hsu ML, Hsu HC, Tzeng CH, Lee SS, Shiao MS and Ho CK: The anti-tumor effect of Ganoderma Lucidum is mediated by cytokines released from activated macrophages and lymphocytes. Int J Cancer 70: 699-705, 1997.
21. Perrot-Applanat M, Deng M, Fernandez H, Lelaidier C, Meduri G and Bouchard P: Immunohistochemical localization of estradiol and progesterone receptors in human uterus throughout pregnancy: expression in endometrial blood vessels. J Clin Endocrinol Metab 78: 216-224, 1994.
22. Shi WL, Wang JD, Fu Y, Xu LK and Zhu PD: The effect of RU486 on progesterone receptor in villous and extravillous trophoblast. Hum Reprod 8: 953-958, 1993.
23. Wang JD, Fu Y, Shi WL, Zhu PD, Qiao GM and Wang YQ: Immunohistochemical localization of estrogen and progesterone receptor in decidua and villi of human early pregnancy. Reprod Contracept 4: 63-69, 1992.
24. Younes MA, Besch NF and Besch PK: Estradiol and progesterone binding in human term placental cytosol. Am J Obstet Gynecol 141: 170-174, 1981.
25. Bischof P, Sizonenko MT and Hermann WL: Trophoblast and decidual response to RU486: effects on human chorionic gonadotropin, human placental lactogen, prolactin and pregnancyassociated plasma protein-A production in vitro. Hum Reprod 1: 3-6, 1986.
26. Das C and Catt KJ: Antifertility actions of the progesterone antagonist RU486 include direct inhibition of placental hormone secretion. Lancet ii: 599-601, 1987.
27. Perry RR, Kang Y and Greaves B: Effects of tamoxifen on growth and apoptosis of estrogen-dependent and independent human breast cancer cells. Ann Surg Oncol 2: 238-245, 1995.
28. Chen H, Tritton TR, Kenny N, Abshcr M and Chiu JF: Tamoxifen induces TGF-beta 1 activity and apoptosis of human MCF-7 breast cancer cells in vitro. J Cell Biochem 61: 9-17, 1996.
29. Oberhammer F, Fritsch G, Schmied M, Pavelka M, Printz D, Purchio T, Lassmann H and Schulte-Hermann R: Condensation of the chromatin at the membrane of an apoptotic nucleus is not associated with activation of an endonuclease. J Cell Sci 104: 317-326, 1993.
30. Oberhammer F, Wilson JW, Dive C, Morris ID, Hickman JA, Wakeling AE, Walker PR and Sikorska M: Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 12: 3679-3684, 1993.
31. Soussi T, Legros Y, Lubin R, Ory K and Schlichtholz B: Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 57: 1-9, 1994.
32. Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB: Wildtype p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491-7495, 1992.
33. Lowe SW, Ruley ER, Jacks T and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
34. Yamamoto M, Maehara Y, Sakaguchi Y, Kusumoto T, Ichiyoshi Y and Sugimachi K: Transforming growth factor-β1 induces apoptosis in gastric cancer cells through a p53-independent pathway. Cancer 77: 1628-1633, 1996.